Skip to content
Medical InsightsKoreaMedical Insights Korea

Overactive Bladder

I have high blood pressure. Can I still take mirabegron for my bladder?

Usually yes, with monitoring. In 2,091 Korean patients, 8.8 percent saw systolic pressure rise by 10 mmHg or more after three months, and 2.3 percent by 20 mmHg or more.

Reported by

Reporter

Sources
2 cited
Published
Reading time
5 minutes

Answer

Mirabegron can usually be taken alongside hypertension provided blood pressure is monitored: in a Korean multicentre study of 2,091 adults prescribed prolonged-release mirabegron 50 mg daily across 95 medical institutions, after three months systolic blood pressure had risen by 10 mmHg or more in 8.8 percent of patients, by 15 mmHg or more in 3.7 percent and by 20 mmHg or more in 2.3 percent, while diastolic pressure rose by 5 mmHg or more in 16.8 percent — an overall picture the authors describe as no clinically meaningful increase, with adverse events in 2.1 percent.

Key takeaways

  • 2,091 Korean adults took prolonged-release mirabegron 50 mg daily for at least three months across 95 medical institutions.
  • Systolic blood pressure rose by 10 mmHg or more in 8.8 percent of patients.
  • It rose by 15 mmHg or more in 3.7 percent and by 20 mmHg or more in 2.3 percent.
  • Diastolic pressure rose by 5 mmHg or more in 16.8 percent and by 10 mmHg or more in 6.7 percent.
  • The overall adverse event rate was 2.1 percent and the events were mostly mild.
  • Mean medication coverage was 73.6 percent, so about a quarter of the nominal exposure did not happen.
  • The study was retrospective with no untreated comparison group, so some of the measured change is ordinary variation in clinic blood pressure.

The warning on mirabegron is usually communicated as a mean rise of a few millimetres of mercury, which is the wrong shape for this decision. Nobody is harmed by an average. People are harmed by being at the top of the distribution, so the useful form of the answer is a set of thresholds.

8.8% / 3.7% / 2.3%

share of 2,091 Korean patients whose systolic blood pressure rose by 10, 15 and 20 mmHg or more after three months on mirabegronLee JH et al., Investigative and Clinical Urology, 2026

Put another way: roughly one patient in eleven will see a systolic rise of at least 10 mmHg, one in twenty-seven at least 15, and one in forty-three at least 20. Diastolic pressure moved more often at the smaller threshold, with 16.8 percent rising by 5 mmHg or more.

What that means if your pressure is already high

Why the alternative is not obviously safer

The drugs mirabegron replaced carry a different risk. A separate Korean analysis of patients aged 65 and over found that antimuscarinics produced a cumulative anticholinergic cognitive burden 15.2 times that of matched patients without overactive bladder, with two-thirds of it attributable to the bladder drug itself — while mirabegron contributed none of it.

So the trade is between a cardiovascular exposure and a cognitive one. In an older patient with well-controlled hypertension, the blood pressure risk is measurable and monitorable and the cognitive one is neither.

How much to trust the figures

This was retrospective with no untreated comparison group. Blood pressure measured in a clinic three months apart moves for reasons unconnected to any drug — season, time of day, cuff, whether you hurried in — so some share of the 8.8 percent is that noise, and the study cannot say how much. Mean medication coverage was also 73.6 percent, meaning a quarter of the exposure being measured did not actually occur, which pushes both the benefit and the risk findings towards zero.

Sources

  1. 1

    Lee JH, Kim A, Shim JS, Ko KJ

    Blood pressure increases and other safety and medication compliance in overactive bladder patients treated with Selebeta PR tablets: A noninterventional, multicenter, retrospective observational study

    Investigative and Clinical Urology 2026;67(3):273-280

    doi:10.4111/icu.20250489 · PMID:42065663

    https://doi.org/10.4111/icu.20250489
  2. 2

    Lee KS, Cho J, Kang D, Ko KJ, Foo CY, Stoelzel M, Hadi FA, Kim S

    A Retrospective Database Analysis of Anticholinergic Burden Among Older Patients With and Without Overactive Bladder in South Korea

    International Neurourology Journal 2025;29(3):188-196

    doi:10.5213/inj.2550112.056 · PMID:41077792

    https://doi.org/10.5213/inj.2550112.056